Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1158/1538-7445.am2019-4819

Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma

..., Alessandro D. Santin
50
Cancer Research11.20
Volume: 79, Issue: 13_Supplement, Pages: 4819 - 4819
Published: Jul 1, 2019
Abstract
Objective: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with poor prognosis. Sacituzumab govitecan (IMMU-132) is a novel antibody-drug conjugate (ADC) targeting trophoblast antigen 2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors including USC, to deliver SN-38, the active metabolite of irinotecan. The objective of this study was to preclinically evaluate the efficacy of IMMU-132...
Paper Fields
Paper Details
Title
Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma
DOI
doi.org/10.1158/1538-7445.am2019-4819
Published Date
Jul 1, 2019
Journal
Cancer Research
Volume
79
Issue
13_Supplement
Pages
4819 - 4819
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.